[
  {
    "ts": null,
    "headline": "Waters Corp. stock outperforms competitors on strong trading day",
    "summary": "Waters Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=2b02b09323495d48ce4ca73b6f2f8e025d573a1e22dfc8e1aa47bbd2f8102df5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747328760,
      "headline": "Waters Corp. stock outperforms competitors on strong trading day",
      "id": 134546025,
      "image": "",
      "related": "WAT",
      "source": "MarketWatch",
      "summary": "Waters Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=2b02b09323495d48ce4ca73b6f2f8e025d573a1e22dfc8e1aa47bbd2f8102df5"
    }
  },
  {
    "ts": null,
    "headline": "Waters Corp's India business boosted by rush for weight-loss drugs",
    "summary": "BENGALURU (Reuters) -U.S.-based Waters Corp, which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters.  Semaglutide, the active ingredient in Novo Nordisk's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving the way for cheaper versions of the drugs.  Local drugmakers including Biocon, Cipla, Dr. Reddy's and Lupin have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.",
    "url": "https://finnhub.io/api/news?id=c842f06134dadae8d1f7ac362e9f77c1e35ba50ef0286601245be45abedfbb3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747309724,
      "headline": "Waters Corp's India business boosted by rush for weight-loss drugs",
      "id": 134465933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WAT",
      "source": "Yahoo",
      "summary": "BENGALURU (Reuters) -U.S.-based Waters Corp, which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters.  Semaglutide, the active ingredient in Novo Nordisk's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving the way for cheaper versions of the drugs.  Local drugmakers including Biocon, Cipla, Dr. Reddy's and Lupin have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.",
      "url": "https://finnhub.io/api/news?id=c842f06134dadae8d1f7ac362e9f77c1e35ba50ef0286601245be45abedfbb3d"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Research Tools & Consumables Earnings: Danaher (NYSE:DHR) Impresses",
    "summary": "Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its peers.",
    "url": "https://finnhub.io/api/news?id=72e67a9879cf04bbec5bb2a0d379d021c4dcdfad5d49afd5af791d19ec520df9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747280155,
      "headline": "Q1 Research Tools & Consumables Earnings: Danaher (NYSE:DHR) Impresses",
      "id": 134465742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WAT",
      "source": "Yahoo",
      "summary": "Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its peers.",
      "url": "https://finnhub.io/api/news?id=72e67a9879cf04bbec5bb2a0d379d021c4dcdfad5d49afd5af791d19ec520df9"
    }
  }
]